ProQR Therapeutics shares surge 17.15% intraday as company announces investor day and Oppenheimer sets $9 price target.

lunes, 30 de marzo de 2026, 9:46 am ET1 min de lectura
PRQR--
ProQR Therapeutics surged 17.15% intraday, driven by the company's announcement of an investor webinar on April 8 to showcase its AX-0810 and RNA editing pipeline, along with clinical data timelines for new projects. Additionally, Oppenheimer set a $9 price target for PRQR, rating it "Outperform," implying a 409.9% upside.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios